At the news
? BULLISHIMPACT 6/10 8-K filed Nov 12, 2026 at 16:45 ET
InspireMD announced FDA approval of its CGuard Prime TransCarotid Stent System for use in TCAR procedures, doubling the platform's U.S. addressable market to approximately 75,000 annual carotid stenting procedures. The approval is supported by CGUARDIANS II pivotal trial data showing 100% acute device success and zero adverse events at 30 days.
- FDA approved PMA Supplement for CGuard Prime TransCarotid Stent System for TCAR procedures on November 12, 2026.
- Approval doubles CGuard Prime platform's total addressable market in the U.S. with access to over 35,000 TCAR procedures annually.
- TCAR and CAS together represent approximately 75,000 annual carotid stenting procedures in the U.S. per company estimates.
- CGUARDIANS II pivotal trial enrolled 50 patients across 11 sites; at 30 days, 100% acute device success with zero deaths, strokes, myocardial infarctions, or stent thrombosis.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access